A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors

Summary

This is a first in human (FIH) 2-part study using ACTM-838 in patients with advanced solid tumors resistant to standard of care treatment. Part 1a will evaluate dose escalation and Part 1b will evaluate dose expansion.

Timeline

Start

2024-06-05

Primary completion

2025-08-28

Completion

2025-08-28

Outcome

Outcome not reported

Stopped (Business): “Sponsor's strategic business decision”

Drugs

Indications